EF Hutton raised the firm’s price target on Hoth Therapeutics to $7 from $6.50 and keeps a Buy rating on the shares following the Q4 report. The higher target reflect Hoth’s higher cash balance and a slightly lower annual cash burn rate this year than expected three months ago, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Biotech Alert: Searches spiking for these stocks today
- Hoth Therapeutics announces positive preclinical research in Alzheimer’s
- Hoth Therapeutics retains Venable to expand patent portfolio
- Hoth Therapeutics engages Altasciences to perform key study for HT-KIT
- Hoth Therapeutics initiated with a Buy at H.C. Wainwright
